← Eichor
Study identifier: NCT05846451 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

Condition: Herbal Interaction  ·  Sponsor: Washington State University

PhaseEARLY_Phase 1
Planned participants16
Who can joinAll sexes, 21 Years to 45 Years
Healthy volunteersYes

About this study

The goal of this study is to investigate whether the botanical product kratom affects how the body processes the opioid drug oxycodone. The main research questions to be answered are two-fold: 1. How does kratom affect the manner in which oxycodone is metabolized (broken down and removed) by the body? 2. Does kratom change the effects oxycodone exerts on the body? Healthy adult participants will complete four study arms, during which they will be given the following: * Kratom (as a tea) * A single dose of oxycodone (as a tablet) * Kratom tea and a single dose of oxycodone * Kratom tea for four days, then kratom tea and a single dose of oxycodone

This description comes directly from the study's public registry record.

Talk to the study team

Mary Paine, PhD  ·  509-358-7759  ·  mary.paine@wsu.edu

Deena Hadi, BS  ·  509-368-6692  ·  deena.hadi@wsu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Washington State University College of Pharmacy and Pharmaceutical SciencesSpokane, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05846451